Geoffrey L. Greene
Director
Ludwig Center at the University of Chicago
Ludwig Institute for Cancer Research
United States of America
Biography
My lab studies the molecular mechanisms by which female steroid hormones regulate development, differentiation and/or cellular proliferation and survival in hormone responsive tissues and cancers. This research has direct relevance to breast cancer genesis, progression, treatment and prevention, as well as to the development of compounds that can be used for hormone replacement therapy in postmenopausal women. The overall objective of my research is to determine the molecular distinctions between estrogen agonism and antagonism in hormone-dependent tissues and cancers and to use this information to identify, develop and characterize novel compounds that can be used for hormone replacement therapy and as breast cancer chemoprevention and chemotherapeutic agents.More recently, we have begun to study the role of cancer stem cells and tumor heterogeneity, focusing especially on the roles and targeting of nuclear receptors in triple negative breast cancer progression and treatment.
Research Interest
Signaling, stem cells, cancer biology
Publications
-
Leong, H., Mathur, P.S., and Greene, G.L. 2009. Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast cancer research and treatment 117, 505-515.
-
Romero, I.L., Lee, W., Mitra, A.K., Gordon, I.O., Zhao, Y., Leonhardt, P., Penicka, C.V., Mui, K.L., Krausz, T.N., Greene, G.L., et al. 2011. The effects of 17beta-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol.
-
Walker, M.P., Zhang, M., Le, T.P., Wu, P., Laine, M., and Greene, G.L. 2011. RAC3 is a pro-migratory co-activator of ERalpha. Oncogene.
